Is Autosomal Dominant Polycystic Kidney Disease Becoming a Pediatric Disorder?

Area of Science:

• Nephrology
• Genetics
• Pediatrics

Background:

• Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of renal failure, affecting 1 in 400-1,000 live births.
• While no cure exists, managing hypertension and proteinuria can slow disease progression.
• Tolvaptan is the only drug recommended in Europe for specific adult ADPKD patients with rapid progression.

Purpose of the Study:

• To review the spectrum of pediatric ADPKD.
• To discuss the pros and cons of genetic testing for at-risk children.
• To highlight challenges and unmet needs in pediatric ADPKD care.

Main Methods:

• Literature review of pediatric ADPKD.
• Discussion of diagnostic and management strategies.
• Analysis of current controversies in pediatric testing.

Main Results:

• ADPKD begins early in life, often in utero, and is not solely an adult-onset disease.
• Hypertension and proteinuria in children correlate with ADPKD severity.
• Controversy exists regarding the testing of at-risk children for ADPKD.

Conclusions:

• Preventive interventions for ADPKD should be considered early, before significant renal damage occurs.
• The early onset of ADPKD necessitates a re-evaluation of its classification as an adult-onset disease.
• Further research and clear guidelines are needed for pediatric ADPKD diagnosis and management.